Company: SCLXW
Filing Date: 2025-01-17
Form Type: 10-Q
Source: 0000950170-25-006755
Chunk: 124

Company: Scilex Holding Co
Filing Date: 2025-01-17
Form: 10-Q
Item: Item 1
Chunk 124
---
 Total SP-102

    245

    1,047

    (802
    )

    SP-103

    Contracted R&D

    1,160

    910

    250

    Personnel

    205

    286

    (81
    )

    Other

    41

    74

    (33
    )

    Total SP-103

    1,406

    1,270

    136

    SP-104

    Contracted R&D

    3

    312

    (309
    )

    Personnel

    (2
    )

    155

    (157
    )

    Other

    (30
    )

    41

    (71
    )

    Total SP-104

    (29
    )

    508

    (537
    )

    GLOPERBA

    Contracted R&D

    94

    173

    (79
    )

    Personnel

    132

    182

    (50
    )

    Other

    32

    28

    4

    Total GLOPERBA

    258

    383

    (125
    )

    ELYXYB

    Contracted R&D

    160

    533

    (373
    )

    Personnel

    263

    271

    (8
    )

    Other

    46

    60

    (14
    )

    Total ELYXYB

    469

    864

    (395
    )

    Total Research and Development Expenses
     
    $
    2,349

    $
    4,072

    $
    (1,723
    )

Research and development expenses for the three months ended September 30, 2024 and 2023 were $2.3 million and $4.1 million, respectively. The $1.8 million decrease was primarily attributed to reduced development costs of SP-102 and SP-104.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the three months ended September 30, 2024 and 2023 were $29.7 million and $40.4 million, respectively. The decrease of approximately $10.7 million was primarily due to a $11.6 million decrease in advisory and financing expenses,